Servier Options MacroGenics’ Phase I Cancer Immunotherapy
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 12 (Table of Contents)
Published: 22 Dec-2011
DOI: 10.3833/pdr.v2011.i12.1640 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
French pharmaceutical company Les Laboratoires Servier has purchased a licence option to develop and commercialise MacroGenics’ MGA271, an immune-stimulating antibody for the potential treatment of solid tumours, in a deal potentially worth up to US$450 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS